Form SC 13D ATHENAHEALTH INC Filed by: ELLIOTT ASSOCIATES, L.P.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Athenahealth (ATHN) 'Looks Forward' to Discussions with Elliot Management as Shares Surge
May 18, 2017 1:20 PM EDTAthenahealth (NASDAQ: ATHN) said it was aware of Elliot's Management new stake in the company and looks forward to discussing the firm views and the company's actions being taken to enhance shareholder value.
"We are aware of Elliots filing and... More
athenahealth (ATHN) PT Raised to $147 at Evercore ISI Following Elliott 13D
May 18, 2017 10:45 AM EDTEvercore ISI raised its price target on athenahealth (NASDAQ: ATHN) to $147.00 (from $118.00) while maintaining a Outperform rating following the Elliott Associates 13D.
Analyst Ross Muken said while the filing surprised many, it is not altogether shocking that a relatively underperforming, though strategically well-placed... More
UPDATE: Elliott Associates Reports New 9.3% Stake in Athenahealth (ATHN) - 13D
May 18, 2017 8:38 AM EDT(Updated - May 18, 2017 8:42 AM EDT)
In a 13D filing, Elliott Associates reports new 9.2% stake in Athenahealth (NASDAQ: ATHN). Elliott called the share significantly undervalued and represent an attractive investment opportunity. Elliott believe the Issuer operates in a highly strategic area at the intersection of technology and healthcare with a disruptive value proposition, a leading competitive position and a compelling product set, the value of which is not reflected in the Issuer's current market value. Elliott believe that there are numerous operational and strategic opportunities to maximize shareholder value and the... More
